IDEXX Laboratories to Launch Catalyst Dx Chemistry Analyzer Phenobarbital Blood Level Testing Capability at WVC [Trade]
Veterinarians will be able to provide more responsive care to their patients with seizures and easily monitor phenobarbital levels in-house
WESTBROOK, Maine, February 14, 2012—IDEXX Laboratories, Inc. will launch a new capability and expanded menu for the Catalyst Dx Chemistry Analyzer at the 84th Western Veterinary Conference to be held in Las Vegas, Nevada, February 19–23. This new test measures the level of the anticonvulsant drug phenobarbital in less than 15 minutes, offering a long-awaited solution for practices providing care for seizure patients. Measuring phenobarbital blood levels pet-side allows veterinarians to adjust medication in real time, delivering more responsive care to their patients and immediate answers for concerned clients. The IDEXX VetLab Station features an interpretative guide for the results as well as trending reports to help veterinarians make confident treatment decisions more quickly and efficiently. And because of the collaborative approach in the research and development of this new test, the results and interpretive information are directly aligned with the IDEXX Reference Laboratories phenobarbital assay, making result interpretation of both methodologies compatible.
"The clinical significance of this newest innovation is profound, providing effective intervention and efficient therapeutic monitoring for seizuring patients," said Michelle Frye, DVM, SM, IDEXX Medical Affairs Manager. "The ability to have phenobarbital blood levels in real time will let veterinarians act quickly to adjust treatment dosages and deliver more immediate, focused care to their patients. This test will also permit veterinarians to dispense the appropriate dosage of phenobarbital for patients during their visits, minimizing callbacks and inconvenient return trips for clients."
This phenobarbital test is the latest cutting-edge addition for the Catalyst Dx analyzer. With a comprehensive menu of 28 different tests for blood and urine and seven preloaded slide CLIPs, including electrolytes, the analyzer gives veterinarians the option to easily customize profiles or run single slides for unprecedented convenience and flexibility. Together with the ProCyte Dx Hematology Analyzer and the SNAPshot Dx Analyzer, the Catalyst Dx analyzer provides veterinarians with the broadest real-time test offering available.
A select number of clinics are already running the phenobarbital slide on the Catalyst Dx analyzer and it will be made available to all Catalyst Dx customers in April 2012. For more information about the Catalyst Dx analyzer, visit idexx.com/catalyst and see the menu section, or call IDEXX at 1-800-355-2896.
About IDEXX VetLab In-house Analyzers
IDEXX VetLab veterinary analyzers are highly integrated and provide fast and flexible real-time results on patients' blood and urine during the pet’s visit, allowing face-to-face discussions between veterinarians and clients that increase understanding and compliance. The analyzers' diagnostic capabilities include clinical chemistry, electrolytes, hematology with reticulocytes and an advanced five-part differential, endocrinology, blood gas, coagulation, urinalysis and infectious diseases. The IDEXX VetLab Station serves as the in-house laboratory's information management system, integrating results from all the analyzers—including the ProCyte Dx Hematology Analyzer, the Catalyst Dx Chemistry Analyzer and the SNAPshot Dx Analyzer—and IDEXX SNAP point-of-care tests into a single comprehensive and easy-to-use patient report. The report is an excellent client-communication tool and tangible evidence of the value veterinary professionals provide to their patients. The information is stored in the IDEXX VetLab Station's database for easy future reference and historical results-trending capability. IDEXX SmartService Solutions utilizes the Internet to deliver proactive service and support for most IDEXX VetLab instruments.
About IDEXX Laboratories
IDEXX Laboratories, Inc. is a leader in pet healthcare innovation, serving practicing veterinarians around the world with a broad range of diagnostic and information technology-based products and services. IDEXX products enhance the ability of veterinarians to provide advanced medical care, improve staff efficiency and to build more economically successful practices. IDEXX is also a worldwide leader in providing diagnostic tests and information for the production animal industry and tests for the quality and safety of water and milk. Headquartered in Maine, IDEXX Laboratories employs more than 4,900 people and offers products to customers in over 100 countries.
Note Regarding Forward-looking Statements
This press release contains statements about the Company's business prospects and estimates of the Company's financial results for future periods that are forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "expects," "may," "anticipates," "intends," "would," "will," "plans," "believes," "estimates," "should," and similar words and expressions. These statements are based on management's expectations of future events as of the date of this press release, and the Company assumes no obligation to update any forward-looking statements as a result of new information or future events or developments. Actual results could differ materially from management's expectations. Factors that could cause or contribute to such differences include the following: the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the Company's ability to develop, manufacture, introduce and market new products and enhancements to existing products; the impact of a weak economy on demand for the Company's products and services; the effectiveness of the Company's sales and marketing activities; disruptions, shortages or pricing changes that affect the Company's purchases of products and materials from third parties, including from sole source suppliers; the Company's ability to manufacture complex biologic products; the effect of government regulation on the Company's business, including government decisions about whether and when to approve the Company's products and decisions regarding labeling, manufacturing and marketing products; changes or trends in veterinary medicine that affect the rate of use of the Company's products and services by veterinarians; the effects of operations outside the U.S., including from currency fluctuations, different regulatory, political and economic conditions, and different market conditions; and the effects of interruptions to the Company's operations due to natural disasters or system failures. A further description of these and other factors can be found in the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, in the section captioned "Risk Factors."
Senior Marketing Manager